Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026

Same author

Cytotoxic CD39<sup>+</sup> tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Science immunology·2026

Same author

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Leukemia·2026

Same author

NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors.

Nature communications·2026

Same author

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Blood advances·2026

Same author

Ablation of prostaglandin E<sub>2</sub> signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

Nature biomedical engineering·2026

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

CAR T cells for solid tumors - developments to watch in 2023

Marcel P Trefny¹, Sebastian Kobold^1,2,3

¹Division of Clinical Pharmacology, University Hospital, Munich, Germany.

Expert Opinion on Biological Therapy

|March 25, 2024

Summary

No abstract available in PubMed .

Keywords:

CAR T cells CAR Targets T cell migration cellular Immunotherapy clinical trials microbiome solid tumors

More Related Videos

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jun 29, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024